Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial

Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial

Background: MET-signaling and midkine (ALK ligand) promote glioma cell maintenance and resistance against anticancer therapies. ALK and c-MET inhibition with crizotinib have a preclinical therapeutic rationale to be tested in newly diagnosed GBM. Methods: Eligible patients received crizotinib with s...

Full description

Bibliographic Details
Main Authors: María Martínez-García, Guillermo Velasco, Estela Pineda, Miguel Gil-Gil, Francesc Alameda, Jaume Capellades, Mari Cruz Martín-Soberón, Israel López-Valero, Elena Tovar Ambel, Palmira Foro, Álvaro Taus, Montserrat Arumi, Aurelio Hernández-Laín, Juan Manuel Sepúlveda-Sánchez
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Cancers
Subjects:
glioblastoma
crizotinib
temozolomide
radiotherapy
midkine
Online Access:https://www.mdpi.com/2072-6694/14/10/2393

Similar Items

Similar Items